Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
49 stocks in the Americas match these filters · market cap, largest first. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | Cell therapy | $4.14B | $21.30 | −43.20% | +10.53% |
| IOVA | Iovance Biotherapeutics, Inc. | Cell therapy | $3.82B | $8.44 | −9.83% | +72.24% |
| MESO | Mesoblast Limited | Cell therapy | $2.23B | $17.19 | −20.05% | +18.06% |
| VCEL | Vericel Corporation | Cell therapy |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $2.21B |
| $43.22 |
| −12.37% |
| −4.63% |
| BLFS | BioLife Solutions, Inc. | Cell therapy | $1.82B | $37.22 | −2.31% | +24.94% |
| VOR | Vor Biopharma Inc. | Cell therapy | $1.30B | $24.01 | −52.17% | +23.51% |
| SANA | Sana Biotechnology, Inc. | Cell therapy | $1.23B | $4.10 | −37.40% | +25.00% |
| IMMX | Immix Biopharma, Inc. | Cell therapy | $968.90M | $14.47 | −4.17% | +66.51% |
| CYRX | Cryoport, Inc. | Cell therapy | $846.85M | $16.72 | −2.79% | +10.36% |
| ALLO | Allogene Therapeutics, Inc. | Cell therapy | $749.72M | $2.17 | −51.35% | +24.00% |
| PROK | ProKidney Corp. | Cell therapy | $690.59M | $1.73 | −50.29% | +12.34% |
| AUTL | Autolus Therapeutics plc | Cell therapy | $649.44M | $2.44 | −5.43% | +67.12% |
| ARTV | Artiva Biotherapeutics, Inc. | Cell therapy | $575.44M | $11.77 | −19.00% | +14.05% |
| KYTX | Kyverna Therapeutics, Inc. | Cell therapy | $546.70M | $8.84 | −35.33% | +11.62% |
| CABA | Cabaletta Bio, Inc. | Cell therapy | $545.94M | $3.22 | −23.88% | +18.38% |
| CAPR | Capricor Therapeutics, Inc. | Cell therapy | $481.97M | $8.29 | −79.46% | +18.43% |
| IPSC | Century Therapeutics, Inc. | Cell therapy | $392.93M | $2.17 | −28.62% | +3.83% |
| LYEL | Lyell Immunopharma, Inc. | Cell therapy | $379.58M | $15.49 | −65.58% | +19.52% |
| CLLS | Cellectis S.A. | Cell therapy | $344.40M | $3.42 | −37.59% | +18.34% |
| FATE | Fate Therapeutics, Inc. Common Stock | Cell therapy | $305.54M | $2.55 | −21.05% | +4.94% |
| RNAC | Cartesian Therapeutics, Inc. | Cell therapy | $304.37M | $10.38 | −12.03% | +33.25% |
| LCTX | Lineage Cell Therapeutics, Inc. | Cell therapy | $275.67M | $1.13 | −45.93% | +9.71% |
| NKTX | Nkarta, Inc. | Cell therapy | $194.10M | $2.71 | −27.15% | +19.91% |
| MXCT | MaxCyte, Inc. | Cell therapy | $139.33M | $1.35 | −27.61% | +32.35% |
| ATRA | Atara Biotherapeutics, Inc. | Cell therapy | $98.77M | $9.84 | −48.60% | +27.63% |
| ACET | Adicet Bio, Inc. | Cell therapy | $84.25M | $9.00 | −48.39% | +11.66% |
| INKT | MiNK Therapeutics, Inc. | Cell therapy | $60.32M | $11.38 | −32.98% | +7.46% |
| ALPS | Alps Group Inc | Cell therapy | $52.42M | $0.31 | −89.14% | −32.74% |
| TCRX | TScan Therapeutics, Inc. | Cell therapy | $51.87M | $0.79 | −69.12% | +3.35% |
| TVGN | Tevogen Inc. | Cell therapy | $44.34M | $6.97 | −85.92% | +25.13% |
| DTSQ | DT Cloud Star Acquisition Corporation | Cell therapy | $41.39M | $11.33 | −12.17% | −0.18% |
| CCEL | Cryo-Cell International, Inc. | Cell therapy | $34.67M | $4.30 | −14.17% | +30.30% |
| ESLA | Estrella Immunopharma, Inc. | Cell therapy | $31.97M | $0.73 | −76.75% | −5.48% |
| SVA.TO | Sernova Biotherapeutics Inc | Cell therapy | $30.03M | 0.11 CAD | −45.00% | −8.33% |
| LGVN | Longeveron Inc. | Cell therapy | $21.68M | $0.68 | −44.72% | +11.29% |
| NCEL | NewcelX Ltd. | Cell therapy | $19.83M | $3.48 | −87.58% | −3.33% |
| PLUR | Pluri Inc. | Cell therapy | $17.91M | $1.56 | −72.54% | −4.88% |
| BCDA | BioCardia, Inc. | Cell therapy | $17.11M | $1.13 | −50.66% | +39.51% |
| SNTI | Senti Biosciences Holdings, Inc. | Cell therapy | $12.17M | $0.39 | −86.43% | +4.52% |
| INAB | IN8bio, Inc. | Cell therapy | $11.53M | $1.17 | −57.14% | −1.68% |
| GDTC | CytoMed Therapeutics Limited | Cell therapy | $11.06M | $0.94 | −74.59% | +3.89% |
| FBLG | FibroBiologics, Inc. | Cell therapy | $9.32M | $1.40 | −89.06% | +123.29% |
| CELZ | Creative Medical Technology Holdings, Inc. | Cell therapy | $7.98M | $1.24 | −80.16% | +56.31% |
| ERNA | Ernexa Therapeutics Inc. | Cell therapy | $5.87M | $4.93 | −93.11% | +25.64% |
| PMCB | PharmaCyte Biotech, Inc. | Cell therapy | $5.79M | $0.53 | −65.23% | −10.26% |
| BRTX | BioRestorative Therapies, Inc. | Cell therapy | $5.67M | $0.22 | −88.23% | −19.68% |
| MBIO | Mustang Bio, Inc. | Cell therapy | $4.18M | $0.55 | −70.16% | −1.43% |
| CRBU | Caribou Biosciences, Inc. | Cell therapy | — | $1.76 | −50.21% | +10.69% |
| DTSQU | DT Cloud Star Acquisition Corporation | Cell therapy | — | $11.49 | −33.58% | 0.00% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.